A 53-year-old cisgender man with HIV is seen in clinic to start a new antiretroviral regimen after recently developing renal disease secondary to hepatitis C virus (HCV)-associated membranoproliferative glomerulonephritis. His estimated glomerular filtration rate recently decreased to 45 mL/min. He is HLA-B*5701 positive. He is currently taking rilpivirine-tenofovir DF-emtricitabine. His HIV RNA has been suppressed for 3 years, and he has no history of virologic failure or antiretroviral drug resistance.